Holocene Advisors LP Sells 5,624,394 Shares of GSK plc (NYSE:GSK)

Holocene Advisors LP lowered its position in GSK plc (NYSE:GSK) by 98.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 65,301 shares of the pharmaceutical company’s stock after selling 5,624,394 shares during the period. Holocene Advisors LP’s holdings in GSK were worth $2,670,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in GSK. FMR LLC boosted its holdings in shares of GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC lifted its position in GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares during the period. Primecap Management Co. CA boosted its stake in GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after acquiring an additional 342,365 shares in the last quarter. Provident Trust Co. boosted its stake in GSK by 1.7% during the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after acquiring an additional 66,765 shares in the last quarter. Finally, Equity Investment Corp grew its holdings in GSK by 1.8% in the third quarter. Equity Investment Corp now owns 3,496,254 shares of the pharmaceutical company’s stock worth $142,927,000 after purchasing an additional 63,052 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GSK. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Barclays raised shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Seven investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Up 0.4 %

GSK stock opened at $34.53 on Friday. GSK plc has a one year low of $32.83 and a one year high of $45.92. The business’s fifty day moving average is $36.78 and its 200 day moving average is $39.71. The stock has a market capitalization of $71.57 billion, a PE ratio of 22.42, a price-to-earnings-growth ratio of 1.33 and a beta of 0.64. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.55%. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is presently 99.35%.

Insider Transactions at GSK

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. The trade was a 19.97 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.00% of the company’s stock.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.